Peptide Formulation: Initial Clinical Development, Final Dosage Forms and Life Cycle Management

Register free: ​ https://www.pharmtech.com/pt_w/clinical

Event Overview:

This discussion will center on peptide formulation approaches and the key properties of peptides that result in opportunities and limitations for peptide formulations. Key strategies will be discussed for rapid entry into early clinical development followed by considerations for final drug product dosage form design, and finally, an overview of potential options for peptide product life cycle management.

• Peptide properties and relevance to dosage form design strategy
• Formulations for rapid entry into the clinic
• Strategies for final dosage form selection and development

Key Learning Objectives:

• Attendees should come away with an understanding of:
  • Peptide properties relevant for dosage form design and selection
  • Formulation options for peptides in early development versus strategies for final dosage for design
  • Formulation options and routes of delivery that may represent life cycle options

Who Should Attend:

• Associate Scientist, Scientist, Principal Scientist, Assoc Director, Director, Senior Director, Executive Director, VP for the following:
  • CMC, formulation, pharmaceutical sciences, drug delivery sciences, process development, pharmaceutical and chemical development, product development, pharmaceutical development, pharmaceutical research and development

Speakers:

Christopher A. Rhodes, Ph.D.
Vice President, Scientific Affairs
Pace Life Sciences

Time and Date:

Tuesday, Nov. 30, 2021 at 2pm EST | 1pm CST | 11am PST

On demand available after final airing until November 30, 2022.

Sponsor: Pace Life Sciences

Register free: https://www.pharmtech.com/pt_w/clinical